1. Introduction

Viral vector therapy is an advanced biotechnology technique in which modified viruses are used to deliver therapeutic genetic material into human cells. It is particularly important in gene therapy, genetic disease treatment, cancer treatment and certain emerging regenerative medicine applications.

Common viral vectors include:

Adeno-associated virus (AAV).

Adenovirus vectors.

Lentiviral vectors.

Retroviral vectors.

Herpes simplex virus (HSV) vectors.

Although these technologies offer significant therapeutic opportunities, their manufacturing creates serious regulatory challenges involving biological safety, contamination prevention, genetic stability, manufacturing consistency, patient protection and environmental containment.

In Morocco, viral vector therapy manufacturing is primarily governed through the pharmaceutical regulatory framework, particularly Law No. 17-04 establishing the Code of Medicine and Pharmacy, together with pharmaceutical establishment authorization requirements, manufacturing standards and marketing authorization procedures.

However, Morocco does not appear to have a comprehensive, publicly established regulatory framework specifically dedicated to viral-vector gene therapy manufacturing. This creates an important distinction between general pharmaceutical regulation and specialized advanced-therapy oversight.

The central legal objective is to ensure that every manufactured viral-vector medicinal product meets appropriate standards of quality, safety, efficacy and traceability before being supplied to patients.

2. Legal and Regulatory Framework in Morocco

A. Law No. 17-04: Code of Medicine and Pharmacy

Law No. 17-04, promulgated by Dahir No. 1-06-151 of 22 November 2006, is the principal legislation regulating pharmaceutical products and pharmaceutical establishments in Morocco.

It establishes requirements concerning:

Pharmaceutical manufacturing.

Manufacturing establishment authorization.

Quality control.

Product registration.

Pharmaceutical supervision.

Storage and distribution.

Pharmacovigilance.

Product withdrawal.

Article 7 establishes the requirement for administrative authorization before industrially manufactured medicines can be marketed or distributed.

Article 8 requires appropriate prior testing to demonstrate efficacy, safety and therapeutic value. It also requires manufacturers to establish manufacturing and control methods capable of guaranteeing product quality during industrial production.

Ma Loi+2

These requirements are directly relevant to viral-vector medicinal products.

For example, a company manufacturing an AAV-based gene therapy must demonstrate that its manufacturing process consistently produces a product meeting established quality specifications.

B. Article 20: Good Manufacturing Practices

Article 20 of Law No. 17-04 requires medicines to be manufactured in accordance with Good Manufacturing Practices (GMP) and Good Distribution Practices.

It also requires conformity testing of each manufactured batch before commercialization.

For viral-vector manufacturing, this principle is particularly important because biological products can exhibit variations arising from cell substrates, production processes and purification methods.

Relevant quality considerations include:

Vector identity.

Vector concentration and potency.

Genetic integrity.

Purity.

Residual host-cell proteins and DNA.

Replication-competent viral contaminants.

Microbiological contamination.

Product stability.

Consequently, batch release must be supported by documented quality-control results.

Ma Loi+1

C. Article 117: Responsibility of the Responsible Pharmacist

Article 117 establishes the responsibilities of the responsible pharmacist in pharmaceutical establishments.

These responsibilities include supervision of:

Raw-material purchasing and quality control.

Pharmaceutical manufacturing.

Production-stage testing.

Finished-product testing.

Storage and distribution.

Imported pharmaceutical products.

Finished-product release.

The establishment also bears responsibility under the statutory framework.

This provision is significant for viral-vector manufacturers because specialized biological manufacturing requires effective professional supervision and documented accountability.

A failure to identify contamination, inadequate batch documentation or improper product release may therefore raise questions about both institutional and professional responsibility.

Ma Loi

D. Law No. 10-22 and the Moroccan Agency for Medicines and Health Products

Law No. 10-22 provides for the establishment of the Moroccan Agency for Medicines and Health Products (AMMPS).

The agency's regulatory responsibilities include pharmaceutical oversight and authorization functions.

An important administrative development occurred on 16 June 2025, when responsibilities for authorizing industrial pharmaceutical establishments and pharmaceutical wholesalers were transferred from the General Secretariat of Government to AMMPS.

This is particularly relevant to companies planning to establish viral-vector manufacturing facilities in Morocco.

The authorization of the manufacturing establishment and the authorization of the medicinal product are distinct regulatory matters.

CGEM+1

Official reference: Moroccan Ministry of Health – Applicable health-product regulations.

3. Licensing and Authorization of Viral Vector Manufacturing Facilities

Manufacturing viral vectors for therapeutic applications requires an appropriately authorized pharmaceutical establishment.

A manufacturer cannot assume that authorization to operate an ordinary pharmaceutical production facility automatically authorizes every type of advanced biological manufacturing.

The regulatory assessment should address:

1. Establishment authorization

The manufacturer must obtain the relevant authorization to establish and operate its pharmaceutical manufacturing facility.

2. Technical infrastructure

The facility must have suitable infrastructure for its intended biological manufacturing activities.

3. Professional supervision

Appropriate pharmaceutical and technical personnel must supervise manufacturing and quality operations.

4. Quality-management systems

The manufacturer must maintain documented procedures governing manufacturing, testing, deviations, corrective actions and product release.

5. Regulatory inspection

The competent authority must be able to inspect the facility and assess its compliance with applicable pharmaceutical requirements.

6. Product authorization

The viral-vector medicinal product must satisfy the applicable marketing authorization requirements before ordinary commercialization.

An investigational product may instead require an applicable specific authorization for clinical trials.

Importantly, the precise classification and additional authorization requirements for a particular viral vector should be confirmed with AMMPS and the relevant biosafety authorities.

4. Biosafety Controls in Viral Vector Manufacturing

Biosafety is one of the most important aspects of viral-vector manufacturing.

Viral vectors may be genetically modified to reduce pathogenicity or prevent replication. Nevertheless, manufacturing can involve biological hazards, including accidental exposure, contamination and unintended environmental release.

Morocco is a party to the Cartagena Protocol on Biosafety, which it ratified on 25 April 2011. The Protocol entered into force for Morocco on 24 July 2011.

The national biosafety framework identifies the Department of Sustainable Development as the Protocol's focal point and ONSSA as the competent national authority for relevant administrative functions.

Morocco Biodiversity

Important regulatory limitation

Morocco's published biosafety information has identified the absence of a comprehensive domestic law governing living modified organisms (LMOs).

The national biosafety framework therefore has historically relied on several indirect regulatory instruments and administrative measures.

The Biosafety Clearing-House records also describe limitations in the regulation of contained use and transboundary movement of LMOs. These records are important evidence of a regulatory gap, but they should not be interpreted as proof that every therapeutic viral-vector activity is prohibited.

Biosafety Clearing-House+1

For viral-vector manufacturers, the legal distinction between pharmaceutical product regulation and environmental biosafety regulation is particularly important.

A medicinal product may satisfy pharmaceutical requirements while its manufacturing activities still require separate assessment of biological containment and environmental risks.

Principal biosafety requirements

5. Good Manufacturing Practices for Viral Vector Production

GMP is essential because viral-vector products are complex biological medicines.

The WHO's Good Manufacturing Practices for Biological Products specifically addresses gene therapy products, including viral and non-viral vectors.

It recognizes that biological manufacturing requires careful control of starting materials, cell banks, production processes, purification, formulation and filling.

World Health Organization+1

A. Starting-material control

Manufacturers must establish suitable controls over:

Cell substrates.

Biological starting materials.

Raw materials.

Reagents.

Culture materials.

Reference standards.

The identity, quality and suitability of starting materials must be established.

B. Manufacturing consistency

Manufacturers must demonstrate that the manufacturing process consistently produces viral vectors meeting predefined quality requirements.

This includes appropriate validation of manufacturing processes and analytical methods.

C. Contamination prevention

Manufacturing systems should prevent:

Microbial contamination.

Adventitious viral contamination.

Cross-contamination between products.

Contamination involving cell substrates.

Unintended presence of replication-competent viruses.

D. Purity and potency

A viral-vector product must meet appropriate specifications for purity, identity, potency and safety.

The manufacturer should establish scientifically justified acceptance criteria and demonstrate that the analytical methods are suitable for their intended purposes.

E. Batch release

Each batch must undergo the applicable quality-control procedures before release.

The release decision should be supported by documented testing, manufacturing records and review by authorized personnel.

6. Quality Control and Testing Requirements

Quality control is particularly challenging because viral vectors are biological products whose characteristics can vary between manufacturing batches.

The following areas are especially important:

These controls support the statutory obligation to establish manufacturing and testing methods capable of ensuring product quality.

The manufacturer must also retain appropriate documentation demonstrating that the finished product complies with its approved specifications.

7. Environmental Protection and Biological Waste Management

Viral-vector manufacturing can generate biological waste containing potentially hazardous materials.

Examples include contaminated disposable materials, laboratory waste, production residues and discarded biological materials.

Morocco's environmental legislation, including Law No. 28-00 concerning waste management and disposal, is relevant to the management of waste generated by industrial and biological facilities.

Manufacturers should establish appropriate arrangements for:

Segregation of biological waste.

Safe collection and storage.

Validated treatment or inactivation.

Authorized disposal.

Accident reporting.

Environmental risk management.

The Cartagena Protocol also provides an international framework for biosafety-related risks associated with living modified organisms.

However, whether a particular viral-vector material falls within a specific biosafety procedure depends on its characteristics, intended use and applicable legal classification.

8. Clinical Trials and Authorization of Viral Vector Therapies

Manufacturing authorization alone does not permit a company to market a viral-vector therapy.

The manufacturer must also satisfy the applicable product authorization requirements.

Under Article 7 of Law No. 17-04, specific authorization mechanisms are available for certain investigational medicines and clinical-trial situations.

A viral-vector clinical development programme should address:

Product quality and manufacturing consistency.

Preclinical safety evidence.

Clinical-trial authorization.

Ethical review.

Informed consent.

Adverse-event reporting.

Long-term safety monitoring where appropriate.

Product traceability.

Gene therapies can have effects that persist long after administration. Therefore, long-term follow-up may be particularly important for identifying delayed adverse effects.

The clinical authorization process should distinguish between permission to investigate a therapy and permission to market it.

9. Importation and Exportation of Viral Vector Materials

Viral-vector manufacturing may involve international transfers of:

Biological starting materials.

Viral-vector products.

Cell banks.

Research materials.

Clinical-trial products.

Finished medicinal products.

Such transfers may raise several independent legal questions.

Pharmaceutical authorization: Does the imported or exported material qualify as a medicinal product subject to pharmaceutical authorization?

Biosafety: Does the material fall within the relevant living modified organism or other biosafety requirements?

Customs compliance: Does the material require specific import or export documentation?

Clinical-trial compliance: Is the transfer connected to an authorized clinical investigation?

Transport safety: Are the applicable biological-material transport requirements satisfied?

Morocco's AMMPS published an import-export guideline for human medicines in May 2026, addressing ordinary marketing authorization and certain specific import situations, including clinical trials.

AMMPS

A manufacturer should not treat an ordinary medicine import authorization as automatically resolving separate biosafety or transport requirements.

10. Institutional Regulatory Responsibilities

Several institutions and regulatory structures may be relevant to viral-vector manufacturing in Morocco.

The precise allocation of authority will depend on the activity and the legal classification of the product or material.

11. Important Case Laws and Their Legal Significance

An important research limitation must be recognized: I could not identify a reported Moroccan court judgment specifically deciding the manufacturing controls for viral-vector gene therapy. Therefore, the following judgments are comparative authorities, not binding Moroccan precedents.

They nevertheless provide useful legal principles for interpreting biosafety, scientific uncertainty, regulatory authorization and pharmaceutical safety.

Case 1. Confédération paysanne and Others v Premier ministre and Ministre de l'Agriculture (2018)

Court: Court of Justice of the European Union

Case number: C-528/16

Citation: ECLI:EU:C:2018:583.

Legal issue: Whether organisms produced using certain genetic modification techniques fall within the European Union's GMO regulatory framework.

Judgment:

The Court held that organisms obtained through newer techniques of mutagenesis could fall within the GMO regulatory framework and could not automatically benefit from exemptions applicable to established techniques with a long safety record.

Relevance to Morocco:

The judgment is useful when assessing the regulatory classification of genetically modified viral vectors.

It demonstrates the importance of examining the technology used and the potential biological risks rather than assuming that every modified biological product falls outside biosafety regulation.

Legal principle: Scientific innovation does not automatically eliminate the need for biosafety assessment.

Source: Read the CJEU judgment – Case C-528/16.

Case 2. Monsanto SAS v Ministre de l'Agriculture et de la Pêche

Court: Court of Justice of the European Union

Case number: C-58/10.

This litigation concerned regulatory classification and authorization under the European GMO framework.

Its significance lies in the relationship between scientific characteristics, intended use and the applicable regulatory classification.

Relevance to viral-vector manufacturing:

The case provides a comparative basis for examining whether a particular genetically modified biological material requires additional regulatory assessment.

However, its conclusions must be distinguished from the specific pharmaceutical authorization requirements applicable to human gene therapy.

Case 3. Brüstle v Greenpeace e.V. (2011)

Court: Court of Justice of the European Union

Case number: C-34/10.

Legal issue: Patentability of inventions involving human embryonic stem cells.

Judgment:

The Court interpreted the European biotechnology patent framework and considered the ethical and legal limitations applicable to inventions involving human embryos.

Relevance to Morocco:

The case is not a viral-vector manufacturing decision. Nevertheless, it illustrates the importance of ethical limitations in advanced biotechnology.

For Moroccan manufacturers, the wider lesson is that pharmaceutical approval, scientific validity and ethical acceptability are distinct legal questions.

Case 4. R v Secretary of State for Health, ex parte Pfizer Ltd (1999)

Court: High Court of Justice, England and Wales.

This case is relevant to the broader administrative-law principle that pharmaceutical regulatory decisions must operate within the applicable statutory framework.

Relevance to Morocco:

A manufacturer challenging an administrative decision concerning its pharmaceutical operations would need to examine the authority's statutory powers, procedural compliance and reasons for the decision.

This is a comparative administrative-law illustration, not a Moroccan viral-vector precedent.

Case 5. United States v Park (1975)

Court: Supreme Court of the United States

Citation: 421 U.S. 658 (1975).

Legal issue: Responsibility of corporate officers for violations of food and drug safety legislation.

Judgment:

The Supreme Court recognized that responsible corporate officers may incur liability under the Federal Food, Drug, and Cosmetic Act where they occupy positions of authority and responsibility concerning regulatory compliance.

Relevance to Morocco:

The decision is useful for understanding why responsibility for manufacturing safety cannot simply be delegated away.

In the Moroccan context, Article 117 of Law No. 17-04 expressly identifies the responsibilities of the responsible pharmacist and the pharmaceutical establishment.

Legal principle: Pharmaceutical safety requires identifiable institutional and professional accountability.

12. Civil, Administrative and Criminal Liability

Viral-vector manufacturing failures can create several forms of legal responsibility.

A. Administrative liability

AMMPS may exercise its statutory regulatory powers in relation to pharmaceutical establishments.

Depending on the applicable legal provisions and circumstances, regulatory non-compliance may result in:

Inspection findings.

Corrective compliance requirements.

Suspension or withdrawal of relevant authorizations.

Restrictions on manufacturing or distribution.

Product withdrawal.

Any administrative action must be based on the competent authority's statutory powers and applicable procedural requirements.

B. Civil liability

A manufacturer may face civil liability where defective manufacturing causes injury.

Potential grounds include:

Negligent manufacturing.

Defective product quality.

Failure to detect contamination.

Inadequate safety warnings.

Failure to conduct appropriate investigations.

Failure to undertake an appropriate product recall.

The injured patient may seek compensation subject to the applicable Moroccan civil-liability rules and proof requirements.

C. Criminal liability

Criminal responsibility may arise where conduct satisfies the elements of an applicable criminal offence.

Examples may include legally punishable conduct involving falsification, fraud, unlawful pharmaceutical activities or serious violations of applicable health and safety legislation.

Criminal liability should not be presumed merely because a manufacturing deviation or adverse event has occurred.

D. Corporate responsibility

The manufacturer must maintain an effective compliance structure.

The responsible pharmacist, technical personnel and corporate management may have different responsibilities depending on their statutory functions and actual conduct.

13. Major Regulatory Challenges in Morocco

Several challenges deserve particular attention.

14. Recommendations for Strengthening Moroccan Regulation

Morocco could strengthen its viral-vector manufacturing framework through the following reforms.

1. Dedicated gene-therapy regulations

Introduce specific regulatory guidance covering AAV, adenovirus, lentivirus and other therapeutic viral-vector platforms.

2. Specialized GMP standards

Establish detailed manufacturing expectations for advanced biological medicinal products, including process validation, analytical testing and batch-release controls.

3. Comprehensive biosafety legislation

Clarify requirements for contained use, handling, transport, storage and disposal of genetically modified viral materials.

4. Regulatory coordination

Develop formal cooperation between AMMPS, the Ministry of Health, ONSSA and environmental authorities.

5. Clinical-trial supervision

Establish clear requirements for clinical-trial manufacturing, investigational product traceability and long-term patient monitoring.

6. Manufacturing inspection capacity

Develop specialist inspection expertise in biological manufacturing, viral-vector quality assurance and contamination control.

7. International regulatory harmonization

Use relevant WHO and ICH standards as technical references while ensuring that their application is consistent with Moroccan legislation.

15. Conclusion

The regulation of viral-vector therapy manufacturing in Morocco is an emerging area of pharmaceutical and biotechnology law.

Law No. 17-04 provides the fundamental legal framework for pharmaceutical manufacturing, quality assurance, product authorization and professional accountability. Law No. 10-22 and the establishment of AMMPS provide an important institutional foundation for strengthening pharmaceutical oversight.

However, viral-vector manufacturing requires more specialized regulation than conventional pharmaceutical manufacturing because of the biological, genetic and environmental risks involved.

The Cartagena Protocol provides an additional international biosafety framework, but Morocco's publicly documented domestic biosafety arrangements reveal gaps concerning comprehensive LMO regulation and contained use.

The principal regulatory challenge is therefore to integrate pharmaceutical GMP, specialized biological quality control, environmental biosafety, clinical-trial supervision and professional accountability into a coherent regulatory system.

Ultimately, effective regulation should ensure that innovation in viral-vector therapy does not compromise patient safety, manufacturing quality or environmental protection.

16. Important Legal References and Research Sources

Useful primary and institutional sources:

WIPO – Moroccan Law No. 17-04.

Moroccan Ministry of Health – Pharmaceutical regulations.

AMMPS – Transfer of pharmaceutical establishment authorization responsibilities.

Morocco – Cartagena Protocol implementation.

WHO – Good Manufacturing Practices for Biological Products.

ICH Q5A(R2) – Viral Safety Evaluation.

Academic research qualification: The comparative judgments discussed above should not be presented as binding Moroccan case law. No directly applicable reported Moroccan viral-vector manufacturing judgment was identified in the sources reviewed. For a formal legal opinion or court submission, the current Arabic Official Bulletin, implementing regulations and published Moroccan judicial decisions should be checked.